Physicians' Academy for Cardiovascular Education

Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi

Video navigation menu

  • The EMPA-REG CV OUTCOME trial of empagliflozin 0:00
  • Heart failure outcomes in the EMPA-REG OUTCOME trial 1:46
  • Does presence of HF at baseline drive the HF outcomes? 2:15
  • What do these results mean for use of diabetes medication in high-risk individuals? 2:58

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: